Fosun Pharma announced that the registration application for the injection of nicorandil developed by its holding subsidiary Chongqing Yaoyou Pharmaceuticals for the treatment of unstable angina has been approved by the National Medical Products Administration. As of May 2024, Fosun Pharma has invested about 4.46 million yuan in the R&D of this new drug.
复星医药：控股子公司新药获批，研发投入446万元
Fosun Pharma: Its subsidiary's new drug has been approved, with R&D investment of 4.46 million yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.